What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane, Breast Cancer
- Main trialPhase 3
- “The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.”In the company’s words, NCT05424835 on ClinicalTrials.gov
- Other names
- SHR1258 · Irene · BLTN
Other drugs for Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up2
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2026 | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | |
| Phase 3Active, not recruiting | Jun 2027 | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | |
| Phase 3Unknown | 30 Dec 2022 | A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | |
| Phase 3Completed | 2 Jun 2023 | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy | |
| Phase 3Unknown | Jun 2023 | A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer | |
| Phase 3Completed | 31 Jan 2024 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | |
| Phase 2Completed | 20 Jun 2019 | A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation | |
| Phase 2Withdrawn | 5 Jun 2025 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | |
| Phase 1Completed | 30 Apr 2020 | A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate | |
| Phase 1Unknown | 28 Jan 2021 | Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer | |
| Phase 1Unknown | May 2021 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | |
| Phase 1Completed | 2 Aug 2022 | Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects | |
| Phase 1Completed | 10 Aug 2022 | Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026